|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Osugi J, Muto S, Matsumura Y, Higuchi M,
Suzuki H and Gotoh M: Prognostic impact of the high-sensitivity
modified Glasgow prognostic score in patients with resectable
non-small cell lung cancer. J Cancer Res Ther. 12:945–951. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Buettner R, Wolf J and Thomas RK: Lessons
learned from lung cancer genomics: The emerging concept of
individualized diagnostics and treatment. J Clin Oncol.
31:1858–1865. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ramnath N, Dilling TJ, Harris LJ, Kim AW,
Michaud GC, Balekian AA, Diekemper R, Detterbeck FC and Arenberg
DA: Treatment of stage III non-small cell lung cancer: Diagnosis
and management of lung cancer, 3rd ed: American college of chest
physicians evidence-based clinical practice guidelines. Chest. 143
5 Suppl:e314S–e340S. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Novaes FT, Cataneo DC, Junior Ruiz RL,
Defaveri J, Michelin OC and Cataneo AJ: Lung cancer: Histology,
staging, treatment and survival. J Bras Pneumol. 34:595–600. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zaporozhchenko IA, Morozkin ES, Skvortsova
TE, Ponomaryova AA, Rykova EY, Cherdyntseva NV, Polovnikov ES,
Pashkovskaya OA, Pokushalov EA, Vlassov VV and Laktionov PP: Plasma
miR-19b and miR-183 as potential biomarkers of lung cancer. PLoS
One. 11:e01652612016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ameres SL and Zamore PD: Diversifying
microRNA sequence and function. Nat Rev Mol Cell Biol. 14:475–488.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen CZ: MicroRNAs as oncogenes and tumor
suppressors. N Engl J Med. 353:1768–1771. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yu N, Zhang Q, Liu Q, Yang J and Zhang S:
A meta-analysis: MicroRNAs' prognostic function in patients with
nonsmall cell lung cancer. Cancer Med. 6:2098–2105. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen Y, Lu L, Feng B, Han S, Cui S, Chu X,
Chen L and Wang R: Non-coding RNAs as emerging regulators of
epithelial to mesenchymal transition in non-small cell lung cancer.
Oncotarget. 8:36787–36799. 2017.PubMed/NCBI
|
|
13
|
Legras A, Pécuchet N, Imbeaud S, Pallier
K, Didelot A, Roussel H, Gibault L, Fabre E, Le Pimpec-Barthes F,
Laurent-Puig P and Blons H: Epithelial-to-mesenchymal transition
and MicroRNAs in lung cancer. Cancers (Basel). 9:pii: E101. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sun Y, Li L, Xing S, Pan Y, Shi Y, Zhang L
and Shen Q: miR-503-3p induces apoptosis of lung cancer cells by
regulating p21 and CDK4 expression. Cancer Biomark. 20:597–608.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li Y, Zhang H, Dong Y, Fan Y, Li Y, Zhao
C, Wang C, Liu J, Li X, Dong M, et al: MiR-146b-5p functions as a
suppressor miRNA and prognosis predictor in non-small cell lung
cancer. J Cancer. 8:1704–1716. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang LX, Hu CY, Jing L, Wang MC, Xu M,
Wang J, Wang Y, Nan KJ and Wang SH: microRNA-219-5p inhibits
epithelial-mesenchymal transition and metastasis of colorectal
cancer by targeting lymphoid enhancer-binding factor 1. Cancer Sci.
108:1985–1995. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wong N and Wang X: miRDB: An online
resource for microRNA target prediction and functional annotations.
Nucleic Acids Res. 43:(Database Issue). D146–D152. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hou J, Meng F, Chan LW, Cho WC and Wong
SC: Circulating plasma MicroRNAs as diagnostic markers for NSCLC.
Front Genet. 7:193eCollection. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Del Vescovo V and Denti MA: microRNA and
lung cancer. Adv Exp Med Biol. 889:153–177. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jiang H, Ju H, Zhang L, Lu H and Jie K:
microRNA-577 suppresses tumor growth and enhances chemosensitivity
in colorectal cancer. J Biochem Mol Toxicol. 31:2017. View Article : Google Scholar
|
|
22
|
Chen XY, Li GM, Dong Q and Peng H: MiR-577
inhibits pancreatic β-cell function and survival by targeting
fibroblast growth factor 21 (FGF-21) in pediatric diabetes. Genet
Mol Res. 14:15462–15470. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang LY, Li B, Jiang HH, Zhuang LW and Liu
Y: Inhibition effect of miR-577 on hepatocellular carcinoma cell
growth via targeting β-catenin. Asian Pac J Trop Med. 8:923–929.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yuan X, He J, Sun F and Gu J: Effects and
interactions of MiR-577 and TSGA10 in regulating esophageal
squamous cell carcinoma. Int J Clin Exp Pathol. 6:2651–2667.
2013.PubMed/NCBI
|
|
25
|
Farazi TA, Juranek SA and Tuschl T: The
growing catalog of small RNAs and their association with distinct
Argonaute/Piwi family members. Development. 135:1201–1214. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Majidinia M, Aghazadeh J,
Jahanban-Esfahlani R and Yousefi B: The roles of Wnt/β-catenin
pathway in tissue development and regenerative medicine. J Cell
Physiol. 233:5598–5612. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Murillo-Garzón V and Kypta R: WNT
signalling in prostate cancer. Nat Rev Urol. 14:683–696. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nusse R and Clevers H: Wnt/β-catenin
signaling, disease, and emerging therapeutic modalities. Cell.
169:985–999. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Katoh M: Differential regulation of WNT2
and WNT2B expression in human cancer. Int J Mol Med. 8:657–660.
2001.PubMed/NCBI
|
|
30
|
Liu C, Li G, Yang N, Su Z, Zhang S, Deng
T, Ren S, Lu S, Tian Y, Liu Y and Qiu Y: miR-324-3p suppresses
migration and invasion by targeting WNT2B in nasopharyngeal
carcinoma. Cancer Cell Int. 17:22017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang H, Fan L, Xia X, Rao Y, Ma Q, Yang J,
Lu Y, Wang C, Ma D and Huang X: Silencing Wnt2B by siRNA
interference inhibits metastasis and enhances chemotherapy
sensitivity in ovarian cancer. Int J Gynecol Cancer. 22:755–761.
2012. View Article : Google Scholar : PubMed/NCBI
|
